TP53 and neoplasm: For example, studies utilizing human triple-negative breast cancer (TNBC) organoids have revealed that the concurrent inhibition of focal adhesion kinase (FAK) and ROS1 leads to a synergistic reduction in tumor proliferation, primarily through the upregulation of p53 signaling pathways and the induction of ferroptosis [51].